 Aridis Pharmaceuticals, Inc. Nasdaq: ARDS, a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the second quarter ended June 30, 2020. 